Direct-acting antivirals in the treatment of hepatitis C virus infection in renal transplant recipients: A single-center experience from South India

Direct-acting antivirals in the treatment of hepatitis C virus infection in renal transplant recipients: A single-center experience from South India

Introduction: Direct-acting antivirals (DAAs) are widely used in the treatment of hepatitis C virus (HCV) infection in renal transplant recipients. Aim: The aim was to study the efficacy and safety of these drugs in our renal transplant recipients. Study Design, Subjects, and Methods: A retrospectiv...

Full description

Bibliographic Details
Main Authors:	T Sugan Gandhi, Gopalakrishnan Natarajan, Dhanapriya Jayachandran, Dinesh Kumar Thanigachalam, Sakthirajan Ramanathan, Sheik Sulthan Alavudeen
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2020-01-01
Series:	Indian Journal of Transplantation
Subjects:	direct-acting antivirals efficacy and safety hepatitis c virus renal transplant recipients south india
Online Access:	http://www.ijtonline.in/article.asp?issn=2212-0017;year=2020;volume=14;issue=2;spage=111;epage=115;aulast=Gandhi

Similar Items

Erythrocytosis in renal transplant recipients: A single-center experience
by: Dhanasekaran Rajasekar, et al.
Published: (2018-01-01)

Shear Wave Elastography for Assessing Liver Stiffness in HCV-Infected Kidney Transplant Recipients after Direct-Acting Antiviral Treatment: A Comparative Study with Magnetic Resonance Elastography
by: Salma Almutawakel, et al.
Published: (2023-12-01)

Editor's Pick: Acute Kidney Injury in Tropical Countries
by: Jeyachandran Dhanapriya, et al.
Published: (2017-07-01)

Immunogenicity of COVID-19 vaccination in kidney transplant recipients
by: V S Jibia, et al.
Published: (2023-01-01)

Interactions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
by: Paolo Carta, et al.
Published: (2020-05-01)

COVID-19 Pandemic – Nephrologist’s Perspective
by: Gopalakrishnan Natarajan, et al.
Published: (2023-01-01)

A study of prevalence and correlates of nonadherence to immunosuppressive medications in renal transplant recipients of South Indian population and their impact on long-term graft function
by: Karunamoorthy Saravanakumar, et al.
Published: (2019-01-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Hansen's disease with lepra reaction presenting with IgA dominant infection related glomerulonephritis
by: Elayaperumal Indhumathi, et al.
Published: (2020-01-01)

Ischemic stroke in a middle-aged renal transplant recipient: A rare cause
by: Abhinesh Vijayakumar, et al.
Published: (2018-01-01)

A study on the prevalence of HCV genotypes and the effect of direct-acting antiviral therapy on clinical and laboratory parameters in HCV-Infected patients at a tertiary care center in North India
by: S Muhammed Shahanas, et al.
Published: (2024-01-01)

Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience
by: Mira Atef, et al.
Published: (2022-09-01)

Evaluation of renal lesions and clinicopathologic correlation in rheumatoid arthritis
by: Periyasamy Muthukumar, et al.
Published: (2017-01-01)

Antineutrophil cytoplasmic antibody-associated vasculitis and chronic lymphocytic leukemia: A rare association
by: Mani Nagarajan, et al.
Published: (2017-01-01)

Crescentic infection related glomerulonephritis in adult and its outcome
by: Ramanathan Sakthirajan, et al.
Published: (2018-01-01)

Paraneoplastic glomerulopathies associated with hematologic malignancies
by: Jeyachandran Dhanapriya, et al.
Published: (2018-01-01)

Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients
by: Soraya Abad, et al.
Published: (2017-03-01)

Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection
by: Ramy H. Agwa, et al.
Published: (2022-02-01)

Hepatitis C: sociodemographic and clinical profile of patients treated with direct-acting antivirals in a pharmaceutical office
by: Karem Aline Pegoraro, et al.
Published: (2023-11-01)

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
by: Nancy Abdel Fattah Ahmed, et al.
Published: (2020-08-01)

Spectrum of biopsy proven renal disease in the elderly – A retrospective observational study from South India
by: Sugan Gandhi Thangaraju, et al.
Published: (2023-01-01)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
by: Chung-Feng Huang, et al.
Published: (2020-07-01)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
by: Asma Ahmed, et al.
Published: (2015-12-01)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
by: Andrea Angeletti, et al.
Published: (2019-02-01)

Coronavirus disease 2019 (COVID-19) in a kidney transplant recipient; case report
by: Martin Thomas Kurian, et al.
Published: (2022-01-01)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
by: Paweł Pabjan, et al.
Published: (2022-01-01)

Cytomegalovirus infection and kidney transplantation- A retrospective study of risk factors and long-term clinical outcome
by: Aravinth Kumar Rajendiran, et al.
Published: (2021-01-01)

The efficacy and safety of direct-acting antiviral agents in patients with chronic HCV infection and UGT1A1*28 polymorphism
by: Lukashyk S.P., et al.
Published: (2020-03-01)

Broad-Spectrum Antivirals Derived from Natural Products
by: Wen-Jun Tian, et al.
Published: (2023-04-01)

Direct-Acting Antiviral Drugs Reduce Fibromyalgia Symptoms in Patients with Chronic Hepatitis C
by: Kuo-Tung Tang, et al.
Published: (2022-09-01)

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
by: Kazuto Tajiri, et al.
Published: (2023-05-01)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
by: Elfi Egmond, et al.

Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
by: Shou-Wu Lee, et al.
Published: (2022-10-01)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
by: Soon Young Ko, et al.
Published: (2018-12-01)

A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
by: Toshifumi Tada, et al.
Published: (2022-01-01)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
by: Christopher Dietz, et al.
Published: (2022-06-01)

Long-term durability of sustained virologic response for hepatitis C virus infection in solid organ transplant recipients receiving direct-acting antivirals
by: Chen-Hua Liu, et al.
Published: (2023-08-01)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
by: Naim Abu-Freha, et al.
Published: (2023-09-01)

Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
by: Mohamed M Sakr, et al.
Published: (2019-01-01)

Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature
by: Mohit Bhatia, et al.
Published: (2020-01-01)